c-MET (T1173I)

MET · Variant type: point · HGVS: p.T1173I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	99.0%	1.0%	92.73
2	Crizotinib	96.8%	3.2%	91.39
3	Capmatinib	96.6%	3.4%	99.75
4	Tepotinib	96.6%	3.4%	99.75
5	Deucravacitinib	95.6%	4.4%	98.99
6	Gilteritinib	94.3%	5.7%	88.97
7	Tivozanib	89.2%	10.8%	92.42
8	Erdafitinib	76.8%	23.2%	95.71
9	Pacritinib	71.7%	28.3%	88.64
10	Repotrectinib	61.2%	38.8%	84.21
11	Canertinib	57.5%	42.5%	96.49
12	Defactinib	54.3%	45.7%	92.68
13	Selpercatinib	47.4%	52.6%	96.72
14	Lenvatinib	45.5%	54.5%	97.74
15	Fedratinib	38.2%	61.8%	96.21
16	Sunitinib	34.0%	66.0%	91.73
17	Fostamatinib	32.8%	67.2%	96.74
18	Abemaciclib	31.2%	68.8%	91.48
19	Afatinib	31.1%	68.9%	98.50
20	Dacomitinib	29.0%	71.0%	97.99
21	Neratinib	27.9%	72.1%	93.18
22	Entrectinib	26.5%	73.5%	93.69
23	Pazopanib	26.3%	73.7%	97.49
24	Vandetanib	26.2%	73.8%	95.74
25	Quizartinib	25.9%	74.1%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	99.0%	—	—
Crizotinib	96.8%	—	—
Capmatinib	96.6%	—	—
Tepotinib	96.6%	—	—
Deucravacitinib	95.6%	—	—
Gilteritinib	94.3%	—	—
Tivozanib	89.2%	—	—
Erdafitinib	76.8%	—	—
Pacritinib	71.7%	—	—
Repotrectinib	61.2%	—	—
Canertinib	57.5%	—	—
Defactinib	54.3%	—	—
Selpercatinib	47.4%	—	—
Lenvatinib	45.5%	—	—
Fedratinib	38.2%	—	—
Sunitinib	34.0%	—	—
Fostamatinib	32.8%	—	—
Abemaciclib	31.2%	—	—
Afatinib	31.1%	—	—
Dacomitinib	29.0%	—	—
Neratinib	27.9%	—	—
Entrectinib	26.5%	—	—
Pazopanib	26.3%	—	—
Vandetanib	26.2%	—	—
Quizartinib	25.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.1ms